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Although the replication cycle of parainfluenza virus type 5 (PIV5) is initially severely impaired in
cells in an interferon (IFN)-induced antiviral state, the virus still targets STAT1 for degradation. As
a consequence, the cells can no longer respond to IFN and after 24”48 h, they go out of the
antiviral state and normal virus replication is established. Following infection of cells in an IFN-
induced antiviral state, viral nucleocapsid proteins are initially localized within small cytoplasmic
bodies, and appearance of these cytoplasmic bodies correlates with the loss of STAT1 from
infected cells. In situ hybridization, using probes specific for the NP and L genes, demonstrated
the presence of virus genomes within these cytoplasmic bodies. These viral cytoplasmic bodies
do not co-localize with cellular markers for stress granules, cytoplasmic P-bodies or
autophagosomes. Furthermore, they are not large insoluble aggregates of viral proteins and/or
nucleocapsids, as they can simply and easily be dispersed by ‘cold-shocking’ live cells, a process
that disrupts the cytoskeleton. Given that during in vivo infections, PIV5 will inevitably infect cells
in an IFN-induced antiviral state, we suggest that these cytoplasmic bodies are areas in which
PIV5 genomes reside whilst the virus dismantles the antiviral state of the cells. Consequently, viral
cytoplasmic bodies may play an important part in the strategy that PIV5 uses to circumvent the
IFN system.
INTRODUCTION
The interferon (IFN) response is initiated when cells
recognize that they have been infected by a virus and
respond by producing IFN-a/b, which can act in a
paracrine and autocrine manner to upregulate the
expression of hundreds of cellular genes, the products of
many having direct or indirect antiviral activity. Cells
recognize that they have been infected by viruses by having
specific intracellular and membrane-bound pattern-recog-
nition receptors (PRRs) which recognize pathogen-asso-
ciated molecular patterns (PAMPs) within certain
products, such as double-stranded RNA or uncapped 59
triphosphorylated single-stranded (ss)RNA, produced dur-
ing virus replication and which are not found in uninfected
cells. Two intracellular PRRs are the DExD/H-box RNA
helicases, retinoic acid inducible gene I (RIG-I) and
melanoma differentiation-associated gene 5 (mda-5).
Once activated by their appropriate ligands, these PRRs
initiate the IFN induction cascade which culminates in the
production of IFN-a/b (for reviews see Pichlmair & Reis e
Sousa, 2007; Saito & Gale, 2007; Randall & Goodbourn,
2008; Takeuchi & Akira, 2008, 2009). The secreted IFN-a/b
then upregulates the expression of IFN-stimulated genes
(ISGs) by activating the Jak/STAT pathway. Briefly,
following binding of IFN-a/b to the type I IFN receptor,
two kinases, Jak1 and tyk2, are activated and, as a result,
phosphorylate the latent cytoplasmic transcription factors
STAT1 and STAT2. These subsequently form stable
heterodimers and migrate to the nucleus where, together
with IFN regulatory factor (IRF)-9, they form an active
transcription complex, termed ISGF3, that initiates tran-
scription of the ISGs (reviewed by Stark et al., 1998;
Platanias, 2005; Randall & Goodbourn, 2008).
Although much has been learnt over recent years about
how paramyxoviruses block aspects of the IFN response
(Haller et al., 2006; Fontana et al., 2008; Randall &
Goodbourn, 2008), much less is known about how viruses
interact with cells in a pre-existing antiviral state, and yet
this may be equally important to viral pathogenesis and
epidemiology. Our studies on parainfluenza virus type 5
(PIV5; formerly known as SV5) have revealed that
although the replication of PIV5 is severely affected in
cells that are in an IFN-induced antiviral state prior to
infection (Carlos et al., 2005, 2007), the virus can dismantle
Four supplementary figures and a high-resolution version of Fig. 5 are
available with the online version of this paper.
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by targeting STAT1 for degradation and, since the cell
cannot maintain the antiviral state indefinitely in the
absence of continuous IFN signalling, a normal pattern of
virus replication is established after 24–48 h (Precious et al.,
2007). When cells are in an IFN-induced antiviral state, as
well as there being a dramatic change in the pattern of
PIV5 protein synthesis (see below), there are also striking
alterations in the distribution of the viral proteins within
the infected cells (Carlos et al., 2005, 2007). Most obviously,
nucleocapsid proteins are located within viral cytoplasmic
bodies rather than being more evenly distributed through-
out the cytoplasm, as occurs in the absence of an IFN
response (Carlos et al., 2005). We have previously suggested
that these viral cytoplasmic bodies are a defence mechanism
in which the virus can hide from intracellular antiviral
responses (Fearns et al., 1994; Chatziandreou et al., 2002;
Carlos et al., 2005). Here, we show that these viral
cytoplasmic bodies are the first structures to be visualized
when cells in an IFN-induced antiviral state become infected
by PIV5. We also show that they contain viral genomes and
that they are not insoluble aggregates as they can quickly be
disrupted by cold-shocking live cells, a procedure that
disrupts the cytoskeleton.
PIV5 is a member of the Paramyxoviridae, a family of
enveloped viruses with single-stranded, negative-sense
RNA genomes. The PIV5 genome is 15246 nucleotides
long and comprises seven genes (Fig. 1) encoding eight
proteins, all of which are structural proteins. Like other
paramyxoviruses, as well as transcribing individual mRNAs
for the viral proteins, the virus must generate full-length
antigenomic and genomic RNAs during replication. Both
genomic and antigenomic RNAs are encapsidated by the
nucleoprotein (NP), forming flexible helical nucleocapsids.
Associated with the nucleocapsid is the viral polymerase
complex comprising the viral large (L) and phospho (P)
proteins. The V protein, which acts as an IFN antagonist by
targeting STAT1 for proteasome-mediated degradation
(Didcock et al., 1999) and inhibiting the activity of mda-
5 (Andrejeva et al., 2004), is also found in low copy
numbers within the virion. The nucleocapsid and asso-
ciated proteins are surrounded by the virus envelope,
which contains three integral membrane proteins – the
haemagglutinin–neuraminidase (HN), fusion (F) and small
hydrophobic (SH) proteins – the matrix (M) protein is
located at the inner surface of the envelope. The viral
polymerase initiates transcription by binding to a promoter
at the 39 end of genomic RNA and, by recognizing gene
start and gene end sequences, sequentially synthesizes
individual capped and polyadenylated mRNAs from the
NP, V/P, M, F, SH, HN and L genes. Due to a specific RNA
editing mechanism, the V/P gene encodes both the V and P
proteins, with the V mRNA being a faithful transcript of
the genomic RNA and the P mRNA having insertion of two
non-templated G residues at the editing site (Thomas et al.,
1988). Since the polymerase only initiates transcription at
the 39 promoter but can disengage the further it proceeds
along the genomic template, there is a transcriptional
gradient in terms of the abundance of the individual
mRNAs, with NP mRNA being the most abundant and L
mRNA the least (Fig. 1; for reviews of the molecular
biology of paramyxoviruses see Whelan et al., 2004; Lamb
& Parks, 2006).
Our previous studies have shown that following infection
of cells in an IFN-induced antiviral state with PIV5, there
are changes in the pattern of virus protein synthesis (Carlos
et al., 2005, 2007; Precious et al., 2007). Whilst there is
downregulation of all viral proteins synthesized, the
expression levels of proteins downstream from the V/P
gene are most severely affected. This can be partially
explained by effects on transcription, in that there is an
increase in the slope of the transcriptional gradient,
possibly because in cells in an IFN-induced antiviral state
the polymerase will disengage more readily from the
genome during transcription. However, there is not
complete concordance between the slope of the transcrip-
tional gradient and the amount of virus protein present
within infected cells; thus IFN must be inducing additional
effects which affect the relative levels of the viral proteins
(Carlos et al., 2005).
METHODS
Cells, viruses and IFN. Vero, MRC5 and A549 cells were grown as
monolayers in 25 or 75 cm
3 tissue culture flasks, in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (growth
medium) or 2% (maintenance medium) fetal calf serum (FCS) at
37 uC. When required, cells were treated with either Roferon A
(Roche; human cells) or recombinant human IFN-aA/D [rHuIFN-aA/
D; PBL Biomedical Laboratories; Vero cells] at 1000 units ml
21. PIV5
Fig. 1. Schematic diagram of the gene order
and the transcript abundance of PIV5 mRNAs
(see text for details). The positions on the
genome map that the NP and L in situ probes
bind to are shown by pink boxes.
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(Baumgartner et al., 1987) were grown and titrated under appropriate
conditions in Vero cells.
Plasmids. Plasmids containing fragments of the NP and L genes of
PIV5 were constructed by cloning PCR-amplified fragments with
EcoRI and HindIII engineered sites for cloning into EcoRI–HindIII-
digested pSPT19 plasmid (Roche), generating pSPT19/PIV5-NP (nt
452–842) and pSPT19/PIV5-L (nt 1953–2355). The plasmid pEH1.4
specifying the probe to mouse gammaherpesvirus-68 (MHV-68)
tRNA 1–4 for use in in situ hybridization is as reported in Bowden et
al. (1997).
In situ hybridization and immunofluorescence. Digoxigenin
(DIG)-labelled ssRNA probes were generated by T7 or SP6
transcription of pSPT19/PIV5-NP or pSPT19/PIV5-L, using the
DIG RNA Labelling kit (Roche) according to the manufacturer’s
instructions. SP6 RNA polymerase was used when preparing NP or L
probes to detect RNA negative-sense viral genomes, while T7 RNA
polymerase was used when preparing NP or L probes to detect
positive-sense RNA antigenome or viral mRNAs. As a negative
control, a DIG-labelled riboprobe encompassing MHV-68 vtRNAs 1–
4 and microRNAs 1–6 was used, which was generated by T7
transcription of pEH1.4 (Bowden et al., 1997). DIG-labelled ribo-
probes were subjected to LiCl/ethanol precipitation for removal of
unincorporated DIG nucleotides. For in situ hybridization analysis,
cells were grown on 13 mm diameter coverslips coated with poly-L-
lysine, in individual wells of a six-well plate. Cells were pretreated for
14 h with 1000 units rHuIFN-aA/D ml
21, or left untreated followed
by infection with either PIV5 W3A or CPI virus at high or low m.o.i.
(or mock infection). After an adsorption period of 1–2 h, the virus
inoculum (or maintenance medium for mock infections) was
removed and replaced with fresh maintenance medium supplemented
or not with rHuIFN-a. Depending on the experiment, the medium on
the untreated cells was either supplemented with rHuIFN-a or left
untreated as a control at 10 h post-infection (p.i.).
At various times p.i., monolayers were fixed (5% formaldehyde and
2% sucrose in PBS) for 15 min at room temperature, washed three
times in PBS and then treated with 2 mg proteinase K ml
21 in 20 mM
Tris pH 7.5/2 mM CaCl2 at 37 uC for 10 min. Proteinase K was
removed and cell monolayers were washed twice with PBS containing
0.1% Tween-20, refixed for 20 min at room temperature and
permeabilized with 0.5% Triton X-100 in PBS supplemented with
2 mM vanadyl ribonucleoside complex (Sigma) for 15 min at room
temperature. Monolayers were subsequently washed three times with
PBS and incubated with 26 sodium chloride–sodium citrate (SSC)
with 0.025% Tween-20 at 37 uC for 5 min. Cells were hybridized to
DIG-labelled riboprobes in hybridization mix (Tris/HCl pH 8.0,
NaH2PO4,N a 2HPO4, Ficol, polyvinyl-pyrrolidone, SSC) supplemen-
ted with 50% formamide, 0.5 mg sonicated salmon sperm ml
21,
0.5 mg tRNA ml
21, 1 mM DTT and RNase inhibitor (RNasin) at
55 uC overnight in a humidified chamber. Cells were washed for
15 min at room temperature with 26 SSC/10 mM Tris pH 7.5 and
then washed with 0.16 SSC/10 mM Tris pH 7.5 for 15 min at room
temperature. A stringent wash (30% formamide, 0.16 SSC, 10 mM
Tris pH 7.5) was carried out at 55 uC for 30 min. Cells were
subsequently washed three times with TBST (150 mM NaCl, 10 mM
KCl, 50 mM Tris pH 7.5, 0.1% Tween-20), and then blocked at room
temperature for 1 h with 2% blocking reagent (Roche) in TBST
supplemented with 20% heat-inactivated sheep serum. Hybridized
probe was detected by incubation of cell monolayers with alkaline-
phosphatase-conjugated anti-DIG Fab fragments (Roche) diluted in
TBST, 2% blocking reagent, 1% heat-inactivated sheep serum for 2 h
at room temperature. When simultaneously detecting NP, the SV5-
NP-a monoclonal antibody (Randall et al., 1987) was appropriately
diluted in the anti-DIG antibody solution. Cells were subsequently
washed several times with TBST and the bound anti-DIG antibody
conjugate was then visualized with the highly sensitive Fast Red Tablet
(Roche) dissolved in 0.4 M NaCl/0.1 M Tris, pH 8.2 for 2 h at 37 uC.
For simultaneous immunofluorescence, FITC-conjugated goat anti-
mouse immunoglobulin was added to the Fast Red solution. The
reaction was stopped by washing monolayers with 0.1% Tween-20 in
PBS, followed by several washes with PBS. For nuclear staining, cells
were also stained with the DNA-binding fluorochrome DAPI (0.5 mg
ml
21; Sigma-Aldrich) for 10 min at room temperature. Monolayers
were washed in PBS and coverslips were mounted onto microscope
slides in the presence of Mowiol mounting medium. A Leica
DM5000B wide-field fluorescence microscope was used to examine
cell monolayers.
Immunofluorescence. For immunofluorescence analysis that was
carried out in the absence of in situ hybridization, cells were grown on
13 mm diameter coverslips (General Scientific) in individual wells of
six-well or 24-well plates. Cells were infected with PIV5 CPI or W3A,
and the inoculum was adsorbed for 1 h. Cells were treated with
exogenous IFN at various times p.i. to monitor the virus replication
cycle after virus transcription and replication had been established. At
various times p.i., monolayers were incubated in fixing solution (5%
formaldehyde and 2% sucrose in PBS) for 15 min at room
temperature, then permeabilized (0.5% Nonidet-P40 and 10%
sucrose in PBS) for 5 min, and washed three times in PBS containing
1% FCS and 0.1% azide (PBS, 1% FCS, 0.1% azide). To detect the
proteins of interest, cell monolayers were incubated with 10–15 ml
appropriately diluted primary antibody for 1 h. The antibody used to
detect PIV5 NP was SV5-NP-a (Randall et al., 1987), stress granules
were detected using a rabbit polyclonal anti-Rck/p54 antibody (MBL
International, code no. PD009) and STAT1 was detected with a rabbit
polyclonal anti-STAT1 antibody (Abcam, ab 2071). Cells were
subsequently washed (PBS, 1% FCS, 0.1% azide) several times and
the antibody–antigen interactions were detected by indirect immuno-
fluorescence (1 h incubation) with FITC- or Texas-red-conjugated
goat anti-rabbit or anti-mouse immunoglobulin (Seralab), as
appropriate. In addition, cells were stained with the DNA-binding
fluorochrome DAPI (0.5 mgml
21; Sigma-Aldrich) for nuclear stain-
ing. Following staining, monolayers were washed with PBS, mounted
using either Citifluor AF-1 mounting solution (Citifluor) or Mowiol
and examined using either a Nikon Microphot-FXA immunofluor-
escence microscope or a Zeiss LSM 5 Exciter confocal microscope.
RESULTS
Detection of virus genomes within CPI-infected
Vero cells that have or have not been treated with
IFN
The CPI strain of PIV5 is unable to block IFN signalling
due to three amino acid changes in its V protein that ablate
its ability to target STAT1 for proteasome-mediated
degradation (Chatziandreou et al., 2002). However, CPI
replicates normally in Vero cells (Carlos et al., 2005, 2007;
Precious et al., 2007) since these cells cannot produce IFN
(Desmyter et al., 1968; Mosca & Pitha, 1986). Therefore, by
infecting cells with CPI and adding IFN at various times
p.i., it is possible to monitor the effects of IFN on the virus
replication cycle after the virus transcription and replica-
tion has been established. In the absence of IFN, following
infection of Vero cells with CPI, virus nucleocapsid
proteins can be detected both throughout the cytoplasm
and in viral cytoplasmic bodies. However, following
PIV5 infection of cells in IFN-induced antiviral state
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have been infected with CPI for 12 h (to allow virus
replication to become established prior to the induction of
an IFN-induced antiviral state), there is a marked
alteration in the distribution of the viral nucleocapsid
proteins compared with untreated cells, in that they are
primarily visualized in cytoplasmic bodies at 36 h p.i.
(Fig. 2 and Carlos et al., 2005).
To determine whether virus genomes are present within
these cytoplasmic bodies, we employed in situ hybridiza-
tion using probes specific for sequences within the NP or L
genes (Fig. 3a, c), which are found at the 39 and 59 ends of
the genome, respectively (Fig. 1). In addition, we also used
probes that hybridized to viral NP or L mRNA, as well as to
antigenomes (Fig. 3b, d). It can be seen that, in general, the
distribution of the virus genomes mirrored the distribution
of the NP as visualized by immunofluorescence (Fig. 3a, c).
Thus, in the absence of IFN, virus genomes were detected
throughout the cytoplasm as well as in cytoplasmic bodies,
whilst after the cells had been treated with IFN, the virus
genomes could only be detected in cytoplasmic bodies,
which also stained with the anti-NP antibody. The pattern
and intensity of the staining was similar regardless of
whether a probe to genomic NP or L sequences was used
(compare Fig. 3a, c), consistent with the binding of the
probes to genomic RNA. In contrast, there was little
concordance between the distribution of the viral NP and
the pattern of staining observed with the probes to viral
mRNA and antigenomes (Fig. 3b, d). Thus, in the absence
of IFN, there was a more even distribution of the in situ
probes throughout the cytoplasm, particularly the probe
specific for NP sequences, presumably reflecting the
distribution of viral mRNA. The intensity of the in situ
hybridization was less when using the probe to L mRNA/
antigenome sequences as compared with the NP probe
(compare Fig. 3b, d). This is consistent with the
transcriptional gradient observed in paramyxovirus-
infected cells, in which genes further away from the 39
promoter are transcribed less frequently than those near
the 39 end of the genome. However, within this pattern of
staining, cytoplasmic bodies could also be visualized,
particularly with the L-specific probe. Furthermore,
cytoplasmic bodies were more evident in cells treated with
IFN, again particularly with the L-specific probe, which
gave relatively little diffuse cytoplasmic staining.
Presumably this reflects the abundance of NP mRNA
compared with L mRNA and the relative abundance of
mRNA to antigenomes in cells treated with IFN. Thus,
these results suggest that in cells treated with IFN the
diffuse staining reflects the distribution of viral mRNA and
the viral antigenomes are primarily located with the
cytoplasmic bodies.
Please note that the in situ RNA probes did not bind non-
specifically to cytoplasmic bodies (Supplementary Fig. S1,
available in JGV Online) and that viral cytoplasmic bodies
are more resistant to the conditions used for in situ
hybridization, i.e. proteinase K and heat treatment, than
the NP, which is more diffusely distributed throughout the
cytoplasm (Supplementary Fig. S2, available in JGV
Online).
Cells on the periphery of plaques developing in
the presence of IFN often only contain small viral
cytoplasmic bodies
Unlike CPI, most PIV5 strains, including the W3A isolate,
limit IFN production by interacting with mda-5
(Andrejeva et al., 2004) and block IFN signalling by
targeting STAT1 for proteasome-mediated degradation
(Didcock et al., 1999). Nevertheless, their ability to
circumvent the IFN response is not absolute. This is
illustrated by differences in the plaque size of PIV5 (W3A)
in cells that can produce and respond to IFN compared
with those in ‘IFN-compromised’ cells. For example, the
plaque size of PIV5 (W3A) is significantly smaller in naı ¨ve
MRC5 cells, which are non-transformed human fibroblasts
that can produce and respond to IFN, compared with
MRC5/BVDV-Npro cells, which cannot produce IFN
Fig. 2. Visualization of viral cytoplasmic bodies in CPI-infected
cells treated with IFN. Vero cell monolayers were infected with CPI
at a high m.o.i. (50–100 p.f.u. per cell). After an adsorption period
of 1–2 h on a rocking platform at 37 6C, the virus inoculum was
removed and replaced with fresh maintenance medium. At 12 h
p.i., the medium was either supplemented with rHuIFN-a or left
untreated as a negative control. At 36 h post treatment, the cells
were fixed and the distribution of the NP was visualized by
immunofluorescence using a Nikon Microphot-FXA immunofluor-
escence microscope.
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infected with CPI at a high m.o.i., and at 8 h p.i., the cells were or were not treated with IFN. At 48 h p.i., the cells were fixed and
co-stained by immunofluorescence, with an antibody to NP, and by in situ hybridization, using probes specific for genomic NP
(a) or L (c) RNA or NP (b) or L (d) antigenomic RNA/mRNA. The cells were also counter-stained with DAPI to reveal the location
of the nuclei. The final column in all four panels is the merged patterns from all three stains. Cells were visualized using a Leica
DM5000B wide-field fluorescence microscope. Note: NP and L probes that bind to the genome should give the same intensity
of staining, whilst the NP probe that binds to mRNA/antigenomes should give more intense staining than the L probe that binds
to mRNA/antigenomes as the abundance of the NP mRNA is significantly greater than that of the L mRNA (see Fig. 1). IF,
Immunofluorescence.
PIV5 infection of cells in IFN-induced antiviral state
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targets IRF-3 for degradation (Hilton et al., 2006) (Fig. 4a).
Similar results were seen following infection of A549 cells
(human lung carcinoma cells that can also produce and
respond to IFN) and A549/BVDV-Npro cells with PIV5
(W3A), although the relative size of the plaques was
smaller than those observed using MRC5 cells (Fig. 4b).
Note that viruses, such as CPI, that cannot target STAT1
for degradation do not form plaques in cells that can
produce and respond to IFN.
To better understand the dynamics of plaque formation in
monolayers of cells that can produce and respond to IFN,
we used immunofluorescence to monitor both viral NP
synthesis and STAT1 degradation in A549 and A549/
BVDV-Npro cells that were or were not pre-treated with
IFN (Fig. 5). As expected from Fig. 4, plaques were
significantly larger in A549/BVDV-Npro cells than in naı ¨ve
A549 cells. Furthermore, in A549/BVDV-Npro cells, the
cells at the edge of the plaque were generally strongly
positive for NP and negative for STAT1. In contrast, in
naı ¨ve A549, whilst the cells at the centre of the plaque were
strongly positive for NP, NP was usually confined within
small cytoplasmic bodies in cells at the edge of the
developing plaque. However, strikingly, these cells were
also negative for STAT1 staining. Presumably the presence
of small viral cytoplasmic bodies in cells at the periphery of
a developing plaque in A549 cells that had not been pre-
treated with exogenous IFN reflects the fact that they had
responded to endogenous IFN produced by cells already
infected within the developing plaque, and were therefore
in an IFN-induced antiviral state when they became
infected. This conclusion is supported by the observation
that pretreatment of either A549 or A549/BVDV-Npro cells
(which can respond to IFN) with IFN reduced the plaque
size further, but again, NP was normally only visualized in
small viral cytoplasmic bodies in cells at the edge of the
developing plaque and these cells were also negative for
STAT1 (Fig. 5).
Note that, although STAT1 rapidly translocates to the
nucleus upon treatment of cells with IFN, the nuclear
localization of STAT1 is transient and by 2–4 h after
treatment with IFN, the majority of STAT1 is located in the
cytoplasm (Supplementary Fig. S3, available in JGV
Online). Furthermore, expression of STAT1 is upregulated
by IFN and as a consequence, the majority of STAT1 is
unphosphorylated and remains in the cytoplasm. Together,
these observations explain the primarily cytoplasmic
distribution of STAT1 observed in cells exposed to IFN
in Fig. 5.
Similar results were obtained with Vero cells, which cannot
produce IFN. In the absence of IFN, plaques on Vero cells
were large and the cells at the edge of a developing plaque
were generally strongly positive for NP and negative for
STAT1. In contrast, in monolayers treated with IFN, the
plaques were much smaller and in many of the cells at the
periphery of developing plaques, the NP protein could only
be visualized in a few, small cytoplasmic bodies. Again,
strikingly, STAT1 was degraded even in cells in which NP
could only be detected in viral cytoplasmic bodies
(Supplementary Fig. S4, available in JGV Online).
Evidence for the presence of genomic RNA within these
small cytoplasmic bodies, visualized around developing
plaques, was obtained by in situ hybridization. Vero cells
were infected with W3A at a low m.o.i. and, at 8 h p.i., IFN
was added to the culture medium. At 48 h p.i., the cells
were fixed and viral genomic RNA was detected using a
probe specific for genomic L sequences. In Fig. 6, two cells
are visible in which large amounts of virus antigen and
genomic RNA can be detected that presumably represent
the initially infected cells. However, in the surrounding
cells, small cytoplasmic bodies which are positive for both
NP and genomic RNA are clearly visible.
PIV5 cytoplasmic bodies do not co-localize with
autophagosomes, P-bodies or stress granules
and are not insoluble aggregates of proteins and
RNA
Morphologically, PIV5 cytoplasmic bodies loosely resemble
cellular structures, such as autophagosomes, P-bodies or
Fig. 4. Plaques of PIV5 strain W3A formed on monolayers of
MRC5, MRC5/BVDV-Npro, A549 and A549/BVDV-Npro. Note
MRC/5BVDV-Npro and A549/BVDV-Npro cells cannot produce
IFN in response to virus infection as BVDV-Npro targets IRF-3 for
degradation (Hilton et al., 2006). MRC5 cells were fixed at 6 days
p.i., whilst the A549 cells were fixed at 10 days p.i.; both were
immunostained with an antibody to PIV5 NP.
T. S. Carlos and others
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of 0.01 p.f.u. per cell. At 4 days p.i., the cells were fixed and co-immunostained for STAT1 and PIV5 NP. Cells were visualized
using a Zeiss LSM 5 Exciter confocal microscope. Arrows highlight cells at the edge of the plaque in which small viral
cytoplasmic bodies can be detected and in which STAT1 has been degraded. A large, high-resolution copy of this image is
available in JGV Online.
PIV5 infection of cells in IFN-induced antiviral state
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degradation of long-lived proteins in the cell but it also has
a role in innate defences against virus infections (reviewed
by Lee & Iwasaki, 2008). mRNA stalled in translation or
targeted for degradation may be located in stress granules
and/or P-bodies. Furthermore, it has been reported that
some viral RNAs and proteins, as well as host cell proteins
with antiviral activity, accumulate in stress granules/P-
bodies (reviewed by Beckham & Parker, 2008). To
determine whether PIV5 cytoplasmic bodies were asso-
ciated with autophagosomes or P-bodies, Vero cells were
transfected with plasmids P62.GFP (Bjorkoy et al., 2005)
and DCP1.GFP (van Dijk et al., 2002) expressing GFP-
tagged marker proteins for autophagosomes or P-bodies,
respectively. At 24 h post-transfection, the cells were
infected with CPI and were treated with IFN 12 h later.
At 18 h post-treatment, the cells were fixed and the
distribution of the markers was compared with that of the
viral cytoplasmic bodies. No co-localization of either
marker was observed with PIV5 cytoplasmic bodies (Fig.
7a, b). Furthermore, using immunofluorescence, no co-
localization between PIV5 cytoplasmic bodies and Rck/p54,
a marker for cellular stress granules, was observed (Fig. 7c).
Indeed, using antibodies against a variety of markers to
cellular structures, including peroxisomes, endosomes,
COP II vesicles, Golgi compartments and actin, we have
so far failed to visualize the co-localization of any cellular
protein/structure with PIV5 cytoplasmic bodies (data not
shown).
Although PIV5 cytoplasmic bodies did not co-localize with
autophagosomes, it was possible that they were insoluble
Fig. 8. Viral cytoplasmic bodies are not large insoluble aggregates
of viral proteins. Vero cells were infected with PIV5 CPI at a high
m.o.i. and were treated with IFN at 8 h p.i. At 48 h p.i., the cells
were or were not cold-shocked for 20 min with ice-cold PBS, after
which time the cells were fixed and the distribution of the PIV5 NP
visualized by immunofluorescence using a Nikon Microphot-FXA
immunofluorescence microscope.
Fig. 7. Viral cytoplasmic bodies do not co-localize with autopha-
gosomes, cellular cytoplasmic P-bodies or stress granules. Vero
cells were transfected with plasmids expressing GFP-tagged
marker proteins for autophagosomes (a; P62.GFP) or P-bodies (b;
DCP1.GFP). At 24 h post-transfection, the cells were infected
with CPI and 12 h later, they were treated with IFN. At 18 h post-
treatment, the cells were fixed and immunostained for NP. (c)
Untransfected cells were infected and treated with IFN as above
and co-stained with an anti-Rck/p54 antibody and an antibody to
PIV5 NP. Cells were visualized using a Nikon Microphot-FXA
immunofluorescence microscope. No co-localization of the marker
proteins and viral proteins was observed.
Fig. 6. Detection of viral genomes in PIV5 cytoplasmic bodies in
cells on the periphery of a developing plaque as PIV5 (W3A)
spreads through a monolayer of cells in an IFN-induced antiviral
state. Vero cells were infected with W3A at an m.o.i. of 0.01 p.f.u.
per cell. At 8 h p.i., IFN was added to the culture medium and, at
48 h p.i., the cells were fixed; the presence of NP was detected by
immunofluorescence and genomic RNA was detected using a
probe specific for L gene sequences as described in the legend to
Fig. 2. Note the presence of low numbers of small viral cytoplasmic
bodies (an example of which is indicated with arrows) in the cells
surrounding the two cells in which large amounts of viral NP
proteins and genomic RNA can be detected. Cells were visualized
using a Leica DM5000B wide-field fluorescence microscope. IF,
Immunofluorescence.
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However, whilst manipulating live cells, we noted, as
shown in Fig. 8, that it was relatively easy to disrupt PIV5
cytoplasmic bodies by treating the cells with cold PBS (a
process known to disrupt microtubules, reviewed by Al-
Fageeh & Smales, 2006) prior to fixation for immuno-
fluorescence analysis (Fig. 8), thereby demonstrating that
they are not insoluble aggregates of protein and/or
nucleocapsids.
DISCUSSION
Although PIV5 limits the amount of IFN induced, and
targets STAT1 for proteasome-mediated degradation, its
ability to circumvent the IFN response is not absolute, as
witnessed by the fact that PIV5 forms smaller plaques on
‘IFN-competent’ cells compared with ‘IFN-compromised’
cells (Fig. 4, see also Young et al., 2003). In vivo cells, such
as plasmacytoid dendritic cells (pDCs), will also produce
large amounts of IFN in the context of an overall immune
response to virus infection (Liu, 2005). Consequently, at
some point during an on-going in vivo infection, PIV5 will
undoubtedly encounter and infect cells that are already in
an IFN-induced antiviral state and the way in which PIV5
(and other viruses) interacts with such cells is likely to
influence its pathogenesis and epidemiology. Results
presented here, and elsewhere, provide a model for how
PIV5 can dismantle an IFN-induced antiviral state of cells,
and suggest a mechanism by which PIV5 is able to establish
prolonged or even persistent infections in vivo.O u r
working model is that upon infection of cells in an IFN-
induced antiviral state, although virus transcription and
protein synthesis are initially severely affected (Carlos et al.,
2005, 2007), PIV5 targets STAT1 for proteasome-mediated
degradation. With the resulting cessation of IFN signalling,
the cells eventually exit their antiviral state and normal
virus replication is established (Precious et al., 2007).
However, until the cells leave the antiviral state, the virus
has to maintain its genome in a functional state within the
infected cell. In situ hybridization evidence presented here
shows that viral genomes are primarily located in
cytoplasmic bodies in cells in an IFN-induced antiviral
state. It is only when the cells exit their antiviral state and
normal virus replication is established that a more diffuse
cytoplasmic distribution of the nucleocapsid proteins and
genomic RNA is observed.
Whilst the biochemical nature of PIV5 cytoplasmic bodies
has to be fully investigated, a number of conclusions can be
drawn. Firstly, whilst PIV5 cytoplasmic bodies clearly
contain genomic RNA, they also probably contain
antigenomic RNA. This latter conclusion is based upon
the observation that in situ hybridization using the L probe
to antigenomic RNA/mRNA readily stains the cytoplasmic
bodies and gives only weak, diffuse cytoplasmic staining,
whilst staining with the NP probe to antigenomic RNA/
mRNA gives much stronger diffuse cytoplasmic staining
(although the cytoplasmic bodies can also be observed).
The diffuse cytoplasmic staining is therefore likely to
represent mRNA, whilst the cytoplasmic body staining is
likely to be due to the presence of antigenomic RNA.
Secondly, PIV5 cytoplasmic bodies are not large insoluble
aggregates of viral nucleocapsids or nucleocapsid proteins
as they can quickly and easily be disrupted by cold-
shocking cells with PBS, a process known to disrupt
microtubules (Al-Fageeh & Smales, 2006). Thirdly, the
cytoplasmic bodies do not co-localize with markers of
autophagosomes, P-bodies or stress granules, and indeed,
we have so far failed to detect any cellular protein that
localizes within or around the viral cytoplasmic bodies,
suggesting they are areas from which cellular proteins may
be excluded. Fourthly, since the L protein can also be
detected in these cytoplasmic bodies (data not shown),
active transcription and replication may occur within the
cytoplasmic bodies, and this is something we are currently
investigating.
The natural history of PIV5 is poorly understood. It has
been isolated on multiple occasions from a variety of
species, and has been linked to prolonged/persistent
infections. For example, it has regularly been isolated from
human tissues and bone marrow cultures, where presum-
ably it must have established a persistent infection.
Furthermore, PIV5 is also regularly isolated in diagnostic
laboratories, although often the original source of virus is
unclear and a matter of debate (reviewed and discussed in
Chatziandreou et al., 2004). Thus, PIV5 is a virus that
continues to circulate within the environment, usually
without having an obvious effect on human or animal
health. Thus, it is possible that the way in which PIV5
interacts with the IFN system, including the formation of
cytoplasmic bodies during its relatively slow spread from
cell to cell in the presence of IFN, may lead to a prolonged,
low-grade infection. This in turn may lead to a situation in
which infected hosts may not be particularly infectious (or
ill) but who would shed virus over prolonged periods of
time, thereby influencing virus epidemiology.
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